ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

Copyleft Clinical Trial Results. You Must Redistribute Slides PEPCAD II ISR Study Paclitaxel-eluting devices: randomized comparison of the SeQuent™ please.
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
EXCELLA BD Randomized Trial 12-month Results
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
TAXUS ATLAS Trial Presented at The EuroPCR meeting Paris, France May 2006 Presented by Dr. Mark Turco TAXUS ATLAS 9-Month Results: Evaluation of TAXUS.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent Didier Carrié, MD,PhD On behalf.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Total Occlusion Study of Canada (TOSCA-2) Trial
Disclosures Runlin Gao has received a research grant
Runlin Gao, M.D. On behalf of ABSORB China Investigators
The Tryton Bifurcation Trial:
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
Stenting of Coronary Arteries in Non Stress/Benestent Disease
TAXUS II and IV: two-year follow-up
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
Kyoto University Hospital, Japan
3-Year Clinical Outcomes From the RESOLUTE US Study
ENDEAVOR IV: 5 Year Final Outcomes
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Presented at ACC 2003 Late Breaking Clinical Trials
The American College of Cardiology Presented by Dr. Raimund Erbel
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
American Heart Association Presented by Dr. Julinda Mehilli
(p = 0.32 for noninferiority)
Drug-eluting stents for in-stent restenosis
European Society of Cardiology Scientific Congress, September 2006
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

ENDEAVOR IV Acronym: ENDEAVOR IV

Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics, 2007

ENDEAVOR IV Randomized Design: 1548 patients were enrolled Subjects: To evaluate treatment with the Endeavor zotarolimus-eluting stent compared with treatment with the Taxus paclitaxel-eluting stent among patients with single de novo coronary lesions Objective : Mean age 63.5 years Mean Patient Age:

ENDEAVOR IV Primary endpoint: Target vessel failure at 9 months Inclusion criteria: Patients with single de novo lesion in native coronary artery with a vessel diameter mm Mean Follow-Up: 12 months

ENDEAVOR IV Patients were randomized to PCI with a zotarolimus-eluting stent (n = 773) or a paclitaxel-eluting stent (n = 775). Predilitation was required. The dose of zotarolimus was 10 µg per mm stent length. Repeat angiographic follow-up was performed at 8 months in a subset of patients (n = 279). Method:

ENDEAVOR IV Baseline clinical characteristics were well-balanced between groups. Prior MI was present in 22%. Treated lesion was the left anterior descending in 42% of patients. The mean baseline percent diameter stenosis was 65%. In the angiographic subgroup (n = 279), late loss was greater in the zotarolimus group than the paclitaxel group both in-stent (0.67 mm vs mm, p < 0.001) and in-segment (0.36 mm vs mm, p = 0.023). Results: Continue..

ENDEAVOR IV Likewise, in-stent percent diameter stenosis was larger in the zotarolimus group (26.4% vs. 16.1%, p < 0.001). Binary stenosis occurred in 13.3% of the zotarolimus group and 6.7% of the paclitaxel group (p = 0.075). The primary endpoint of target vessel failure at 9 months met the noninferiority margin of difference, with an event rate of 6.6% in the zotarolimus group and 7.2% in the paclitaxel group, p < for noninferiority(Fig 1). Continue..

ENDEAVOR IV Legend: The primary endpoint of target vessel failure at 9 months met the noninferiority margin of difference, with an event rate of 6.6% in the zotarolimus group and 7.2% in the paclitaxel group, p < for noninferiority. Target vessel failure rate at 9 months Fig 1 Continue..

ENDEAVOR IV At 1 year, TVF had occurred in 7.7% of the zotarolimus group and 9.4% in the paclitaxel group and MACE in 6.5% and 6.6%, respectively. Among the individual endpoints, there were few deaths (1.1% in each group) or myocardial infarctions (MI) (1.6% vs. 2.6%, respectively, p = 0.21). Target vessel revascularization was similar between groups (6.3% vs. 6.7%, p = 0.75) (Fig 2). Continue..

ENDEAVOR IV Legend: Target vessel revascularization was similar between zotarolimus and paclitaxel group (6.3% vs. 6.7%, p = 0.75) Target vessel revascularization Fig 2 Continue..

ENDEAVOR IV Overall stent thrombosis by 1 year trended higher in the zotarolimus group (0.8% vs. 0.1%, p = 0.124), with 3 of the 6 stent thrombosis events in the zotarolimus group occurring by 30 days and the remaining 3 events occurring at day 83, 145 and 171.

ENDEAVOR IV Among patients undergoing PCI for a single de novo lesion in a native coronary artery, use of a zotarolimus-eluting stent was non-inferior to a paclitaxel-eluting stent for the primary endpoint of target vessel failure at 9 months. The zotarolimus-eluting stent has previously been evaluated in comparison to the sirolimus-eluting stent in the ENDEAVOR 3 trial, which showed significantly greater late lumen loss with the zotarolimus-eluting stent on angiographic follow-up. Similar results were observed in the present study, which showed greater late lumen loss with the zotarolimus-eluting stent when compared to the paclitaxel-eluting stent. The difference in late lumen loss in the angiographic substudy did not translate into a difference in clinical events. Conclusion: Continue..

ENDEAVOR IV While there was no difference in TVF or MACE through 1 year, stent thrombosis trended higher with the zotarolimus-eluting stent. Longer follow-up is needed to determine if the excess in stent thrombosis with the zotarolimus-eluting continues to increase relative to the paclitaxel-eluting stent, as well as a larger experience in more patients to determine if the excess is confirmed.